Company ExpansionThe recent merger with Adaptive Phage Therapy expanded BiomX’s pipeline with BX211, a phage-based therapy developed to treat DFO patients infected with S. aureus.
Efficacy And Clinical OutcomesBX211 showed positive trends across multiple clinical parameters, including higher proportion of visits with no clinical evidence of infection and evidence of resolving DFO by MRI/X-ray.
Financial PerformanceBiomX announced 3Q24 financial results, posting EPS of $0.31 compared with an estimate of ($0.06).